Drug intelligence / Profile preview

Shigella flexneri 2a vaccine

Development stage: Unknown
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Oral, Intranasal, Intramuscular, Intradermal, Subcutaneous

Overview

The Shigella flexneri 2a vaccine is a monovalent Shigella bioconjugate vaccine developed by GlycoVaxyn AG. It is designed to address the critical unmet global health need for an affordable and broadly protective vaccine against Shigella, a leading cause of diarrheal disease and death in young children in low-income countries. The vaccine leverages GlycoVaxyn's innovative *in vivo* glycosylation technology to induce an immune response specifically against *Shigella flexneri 2a*.

Beyond the preview

Go deeper on Shigella flexneri 2a vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shigella flexneri 2a vaccine.

Explore the full profile